Q-omics provides the consensus-scored CDC42P5 profile across patient tissues and cancer cell-line models. CDC42P5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CDC42P5 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, CDC42P5 RNA expression shows 11,319 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, BLCA, and DLBC as cancer lineages where CDC42P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC42P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC42P5 survival associations across molecular data types. CDC42P5 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC42P5 RNA expression–survival associations across cancer types. High CDC42P5 expression shows unfavorable associations in ACC, STAD and ESCA, but favorable associations in UCS, SKCM and LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify ACC as the clearest survival context for CDC42P5 RNA expression.
This table summarizes CDC42P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CDC42P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC42P5 shows lower tumor expression in KICH and THCA and higher tumor expression in BLCA, BRCA, LIHC and KIRC. The BLCA box plot shows higher CDC42P5 RNA expression in tumor versus normal tissue (log2 FC = +0.339, t-test p = .010).
This table shows molecular features associated with CDC42P5 in patient tissues and cancer cell lines. In patient samples, CDC42P5 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
